Cytoskeletal Transport Selectivity Enhancement

Target: KIF5A Composite Score: 0.455 Price: $0.52▲6.0% Citation Quality: Pending neurodegeneration Status: active
☰ Compare⚔ Duel⚛ Collideinteract with this hypothesis
📄 Export → LaTeX
Select venue
arXiv Preprint NeurIPS Nature Methods PLOS ONE
🌐 Open in Overleaf →
📖 Export BibTeX
⚠ Low Validation Senate Quality Gates →
Evidence Strength Pending (0%)
5
Citations
1
Debates
5
Supporting
3
Opposing
Quality Report Card click to collapse
C
Composite: 0.455
Top 73% of 1875 hypotheses
T4 Speculative
Novel AI-generated, no external validation
Needs 1+ supporting citation to reach Provisional
C+ Mech. Plausibility 15% 0.50 Top 76%
C+ Evidence Strength 15% 0.50 Top 57%
C+ Novelty 12% 0.50 Top 82%
C+ Feasibility 12% 0.50 Top 65%
F Impact 12% 0.00 Top 50%
C+ Druggability 10% 0.50 Top 57%
C+ Safety Profile 8% 0.50 Top 57%
C+ Competition 6% 0.50 Top 77%
C+ Data Availability 5% 0.50 Top 71%
C+ Reproducibility 5% 0.50 Top 63%
Evidence
5 supporting | 3 opposing
Citation quality: 0%
Debates
1 session A+
Avg quality: 0.95
Convergence
0.00 F 30 related hypothesis share this target

From Analysis:

How do host cell factors influence the conformation and propagation properties of transmitted pathological seeds?

The abstract acknowledges that host cells influence seed properties, but the specific cellular factors and mechanisms involved are not well understood. This knowledge gap limits our ability to predict disease progression and develop cell-targeted therapies. Gap type: open_question Source paper: Protein transmission in neurodegenerative disease. (2020, Nat Rev Neurol, PMID:32203399)

→ View full analysis & debate transcript

Description

Engineering motor protein adaptors to selectively misroute pathological seeds to degradative compartments

No AI visual card yet

Dimension Scores

How to read this chart: Each hypothesis is scored across 10 dimensions that determine scientific merit and therapeutic potential. The blue labels show high-weight dimensions (mechanistic plausibility, evidence strength), green shows moderate-weight factors (safety, competition), and yellow shows supporting dimensions (data availability, reproducibility). Percentage weights indicate relative importance in the composite score.
Mechanistic 0.50 (15%) Evidence 0.50 (15%) Novelty 0.50 (12%) Feasibility 0.50 (12%) Impact 0.00 (12%) Druggability 0.50 (10%) Safety 0.50 (8%) Competition 0.50 (6%) Data Avail. 0.50 (5%) Reproducible 0.50 (5%) KG Connect 0.50 (8%) 0.455 composite
8 citations 8 with PMID 8 medium Validation: 0% 5 supporting / 3 opposing
For (5)
5
3
(3) Against
High Medium Low
High Medium Low
Evidence Matrix — sortable by strength/year, click Abstract to expand
Evidence Types
1
2
5
MECH 1CLIN 2GENE 5EPID 0
ClaimStanceCategorySourceStrength ↕Year ↕Quality ↕PMIDsAbstract
Genome-wide Analyses Identify KIF5A as a Novel ALS…SupportingGENENeuron MEDIUM2018-PMID:29566793-
Uncomplicated (Pure) Hereditary Spastic Paraplegia…SupportingMECHPubMed MEDIUM1993-PMID:20301682-
Altered molecular and cellular mechanisms in KIF5A…SupportingGENECell Death Dis MEDIUM2024-PMID:39333504-
Clinical and genetic spectra of 1550 index patient…SupportingCLINBrain MEDIUM2022-PMID:34983064-
Hereditary spastic paraplegia: clinico-pathologic …SupportingCLINActa Neuropatho… MEDIUM2013-PMID:23897027-
Recent Updates on the Genetics of Amyotrophic Late…OpposingGENEMol Neurobiol MEDIUM2022-PMID:35768750-
Pathogenic Genome Signatures That Damage Motor Neu…OpposingGENECells MEDIUM2020-PMID:33333804-
Current Knowledge of Endolysosomal and Autophagy D…OpposingGENECells MEDIUM2021-PMID:34359848-
Legacy Card View — expandable citation cards

Supporting Evidence 5

Genome-wide Analyses Identify KIF5A as a Novel ALS Gene. MEDIUM
Neuron · 2018 · PMID:29566793
Uncomplicated (Pure) Hereditary Spastic Paraplegia Overview. MEDIUM
PubMed · 1993 · PMID:20301682
Altered molecular and cellular mechanisms in KIF5A-associated neurodegenerative or neurodevelopmental disorder… MEDIUM
Altered molecular and cellular mechanisms in KIF5A-associated neurodegenerative or neurodevelopmental disorders.
Cell Death Dis · 2024 · PMID:39333504
Clinical and genetic spectra of 1550 index patients with hereditary spastic paraplegia. MEDIUM
Brain · 2022 · PMID:34983064
Hereditary spastic paraplegia: clinico-pathologic features and emerging molecular mechanisms. MEDIUM
Acta Neuropathol · 2013 · PMID:23897027

Opposing Evidence 3

Recent Updates on the Genetics of Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. MEDIUM
Mol Neurobiol · 2022 · PMID:35768750
Pathogenic Genome Signatures That Damage Motor Neurons in Amyotrophic Lateral Sclerosis. MEDIUM
Cells · 2020 · PMID:33333804
Current Knowledge of Endolysosomal and Autophagy Defects in Hereditary Spastic Paraplegia. MEDIUM
Cells · 2021 · PMID:34359848
Multi-persona evaluation: This hypothesis was debated by AI agents with complementary expertise. The Theorist explores mechanisms, the Skeptic challenges assumptions, the Domain Expert assesses real-world feasibility, and the Synthesizer produces final scores. Expand each card to see their arguments.
Gap Analysis | 4 rounds | 2026-04-10 | View Analysis
🧬 Theorist Proposes novel mechanisms and generates creative hypotheses

Based on the knowledge gap regarding host cell factors influencing pathological seed conformation and propagation, here are my novel therapeutic hypotheses:

Hypothesis 1: Chaperone Network Reprogramming Therapy

Description: Host cell chaperone networks (HSP70, HSP90, co-chaperones) can be therapeutically reprogrammed to selectively recognize and refold incoming pathological protein seeds before they template endogenous proteins. By enhancing specific chaperone-co-chaperone complexes while inhibiting others, we can create a cellular environment that converts pathological conformations t

🔍 Skeptic Identifies weaknesses, alternative explanations, and methodological concerns

I'll provide a rigorous critique of each hypothesis, identifying specific weaknesses, alternative explanations, and key experiments needed for falsification.

Hypothesis 1: Chaperone Network Reprogramming Therapy

Confidence: 0.7 → Revised: 0.3

Critical Weaknesses:

  • Oversimplified chaperone selectivity: The hypothesis assumes chaperones can be "reprogrammed" to selectively target pathological conformations without affecting normal protein folding. However, chaperones recognize hydrophobic patches and misfolded structures generally - they lack inherent specificity for pathologi
  • 🎯 Domain Expert Assesses practical feasibility, druggability, and clinical translation

    PRACTICAL FEASIBILITY ASSESSMENT

    Based on my analysis of these hypotheses, I'll assess their druggability, existing therapeutic landscape, and development feasibility:

    HYPOTHESIS 1: Chaperone Network Reprogramming

    DRUGGABILITY: MODERATE

    Existing Chemical Matter:

    • HSP90 inhibitors: Geldanamycin analogs (17-AAG, 17-DMAG) - multiple failed trials
    • HSP70 allosteric modulators: YM-08, JG-98 (tool compounds)
    • Co-chaperone modulators: Limited, mostly academic tools
    Competitive Landscape:
    • Neurimmune/Roche abandoned HSP70 programs after Phase I failures
    • Synta Pharmaceutica

    Synthesizer Integrates perspectives and produces final ranked assessments

    Based on the comprehensive debate analysis, here is my synthesis of the therapeutic hypotheses with scored rankings:

    Price History

    0.460.490.52 0.54 0.43 2026-04-212026-04-252026-04-28 Market PriceScoreevidencedebate 8 events
    7d Trend
    Stable
    7d Momentum
    ▲ 7.4%
    Volatility
    High
    0.0535
    Events (7d)
    7

    Clinical Trials (0)

    No clinical trials data available

    📚 Cited Papers (8)

    No extracted figures yet
    No extracted figures yet
    No extracted figures yet
    No extracted figures yet
    No extracted figures yet
    No extracted figures yet
    No extracted figures yet
    No extracted figures yet

    📅 Citation Freshness Audit

    Freshness score = exp(-age×ln2/5): halves every 5 years. Green >0.6, Amber 0.3–0.6, Red <0.3.

    No citation freshness data yet. Export bibliography — run scripts/audit_citation_freshness.py to populate.

    📙 Related Wiki Pages (0)

    No wiki pages linked to this hypothesis yet.

    ࢐ Browse all wiki pages

    ⚔ Arena Performance

    No arena matches recorded yet. Browse Arenas
    → Browse all arenas & tournaments

    📊 Resource Economics & ROI

    Moderate Efficiency Resource Efficiency Score
    0.50
    32.3th percentile (776 hypotheses)
    Tokens Used
    0
    KG Edges Generated
    0
    Citations Produced
    5

    Cost Ratios

    Cost per KG Edge
    0.00 tokens
    Lower is better (baseline: 2000)
    Cost per Citation
    0.00 tokens
    Lower is better (baseline: 1000)
    Cost per Score Point
    0.00 tokens
    Tokens / composite_score

    Score Impact

    Efficiency Boost to Composite
    +0.050
    10% weight of efficiency score
    Adjusted Composite
    0.505

    How Economics Pricing Works

    Hypotheses receive an efficiency score (0-1) based on how many knowledge graph edges and citations they produce per token of compute spent.

    High-efficiency hypotheses (score >= 0.8) get a price premium in the market, pulling their price toward $0.580.

    Low-efficiency hypotheses (score < 0.6) receive a discount, pulling their price toward $0.420.

    Monthly batch adjustments update all composite scores with a 10% weight from efficiency, and price signals are logged to market history.

    📋 Reviews View all →

    Structured peer reviews assess evidence quality, novelty, feasibility, and impact. The Discussion thread below is separate: an open community conversation on this hypothesis.

    💬 Discussion

    No DepMap CRISPR Chronos data found for KIF5A.

    Run python3 scripts/backfill_hypothesis_depmap.py to populate.

    No curated ClinVar variants loaded for this hypothesis.

    Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.

    🔍 Search ClinVar for KIF5A →
    Loading history…

    ⚖️ Governance History

    No governance decisions recorded for this hypothesis.

    Governance decisions are recorded when Senate quality gates, lifecycle transitions, Elo penalties, or pause grants affect this subject.

    Browse all governance decisions →

    KG Entities (33)

    ATF5ATP6V1AFUSHMGCRHSPA1AKIF5ALTN1UPRmtbenign or degradable formsbiomolecular condensateschaperone-co-chaperone complexesconformational selectivitydegradative compartmentslysosomal acidificationlysosomal pHmembrane lipid compositionmitochondrial proteostasismotor protein adaptorsneurodegenerationpathological conformations

    Related Hypotheses

    Gut Microbiome Remodeling to Prevent Systemic NLRP3 Priming in Neurodegeneration
    Score: 0.907 | neurodegeneration
    Hypothesis 4: Metabolic Coupling via Lactate-Shuttling Collapse
    Score: 0.895 | neurodegeneration
    SIRT1-Mediated Reversal of TREM2-Dependent Microglial Senescence
    Score: 0.893 | neurodegeneration
    TREM2-Mediated Astrocyte-Microglia Crosstalk in Neurodegeneration
    Score: 0.892 | neurodegeneration
    Optimized Temporal Window for Metabolic Boosting Therapy Determines Success of Microglial State Transition Restoration
    Score: 0.887 | neurodegeneration

    Estimated Development

    Estimated Cost
    $0
    Timeline
    0 months

    🧪 Falsifiable Predictions (2)

    2 total 0 confirmed 0 falsified
    IF we engineer a KIF5A adaptor protein containing a LC3-interacting region (LIR) fused to a pathological seed-recognizing domain and express it in motor neurons derived from ALS/FTD patients with TDP-43 pathology, THEN we will observe a ≥40% reduction in cytoplasmic TDP-43 aggregates and a ≥2-fold increase in colocalization with LAMP2-positive lysosomal compartments within 72 hours post-transduction.
    pending conf: 0.35
    Expected outcome: ≥40% reduction in TDP-43 aggregate burden; ≥2-fold increase in lysosomal co-localization
    Falsified by: No significant change in TDP-43 aggregation patterns (<20% reduction) and no change in lysosomal trafficking metrics compared to empty vector controls
    Method: iPSC-derived motor neurons from ALS/FTD patients (n≥3 lines) transduced with engineered KIF5A adaptor constructs, analyzed by immunofluorescence and biochemical fractionation at 72h post-transduction
    IF we administer a single intrathecal injection of AAV9 encoding an engineered KIF5A adaptor with lysosomal targeting domains to 8-week-old SOD1G93A mice (a model of ALS), THEN we will observe delayed onset of hindlimb paralysis by ≥10 days and a ≥50% reduction in spinal cord motor neuron inclusions compared to AAV9-GFP control mice at 16 weeks of age.
    pending conf: 0.28
    Expected outcome: Delayed disease onset by ≥10 days; ≥50% reduction in motor neuron inclusions
    Falsified by: No significant difference in disease onset (difference <5 days) or no reduction in aggregate burden in motor neurons compared to GFP control group
    Method: Randomized controlled trial in SOD1G93A mice (n≥12 per group), intrathecal AAV9 delivery at 8 weeks, behavioral monitoring (rotarod, grip strength) and histopathological analysis at 16 weeks

    Knowledge Subgraph (25 edges)

    associated with (2)

    LTN1ribosome-associated quality controlATP6V1Aneurodegeneration

    converts (1)

    pathological conformationsbenign or degradable forms

    distinguishes (2)

    conformational selectivitypathological protein statesconformational selectivityphysiological protein states

    drives (1)

    FUSphase separation

    eliminates (1)

    ribosome-associated quality controlseed-templated nascent proteins

    enables (1)

    lysosomal acidificationprotein degradation

    encodes (1)

    KIF5Amotor protein adaptors

    encodes subunit of (2)

    ATP6V1Av-ATPaseATP6V1Alysosomal acidification

    enhances (1)

    HSPA1Achaperone-co-chaperone complexes

    facilitates (2)

    HSPA1Aprotein foldingbiomolecular condensatesseed propagation

    forms (1)

    phase separationbiomolecular condensates

    misdirects (1)

    motor protein adaptorspathological seeds

    modulates (3)

    v-ATPaselysosomal pHHMGCRmembrane lipid compositionmembrane lipid compositionseed uptake

    prevents (1)

    protein foldingprotein aggregation

    protects against (1)

    protein degradationneurodegeneration

    regulates (1)

    UPRmtmitochondrial proteostasis

    resists (1)

    mitochondrial proteostasisseed-induced protein misfolding

    targets (1)

    pathological seedsdegradative compartments

    transcriptional activator of (1)

    ATF5UPRmt

    Mechanism Pathway for KIF5A

    Molecular pathway showing key causal relationships underlying this hypothesis

    graph TD
        ATP6V1A["ATP6V1A"] -->|encodes subunit of| v_ATPase["v-ATPase"]
        ATP6V1A_1["ATP6V1A"] -->|encodes subunit of| lysosomal_acidification["lysosomal acidification"]
        v_ATPase_2["v-ATPase"] -->|modulates| lysosomal_pH["lysosomal pH"]
        lysosomal_acidification_3["lysosomal acidification"] -->|enables| protein_degradation["protein degradation"]
        protein_degradation_4["protein degradation"] -->|protects against| neurodegeneration["neurodegeneration"]
        ATF5["ATF5"] -->|transcriptional ac| UPRmt["UPRmt"]
        UPRmt_5["UPRmt"] -->|regulates| mitochondrial_proteostasi["mitochondrial proteostasis"]
        mitochondrial_proteostasi_6["mitochondrial proteostasis"] -->|resists| seed_induced_protein_misf["seed-induced protein misfolding"]
        HSPA1A["HSPA1A"] -->|facilitates| protein_folding["protein folding"]
        HSPA1A_7["HSPA1A"] -->|enhances| chaperone_co_chaperone_co["chaperone-co-chaperone complexes"]
        protein_folding_8["protein folding"] -->|prevents| protein_aggregation["protein aggregation"]
        pathological_conformation["pathological conformations"] -->|converts| benign_or_degradable_form["benign or degradable forms"]
        style ATP6V1A fill:#ce93d8,stroke:#333,color:#000
        style v_ATPase fill:#4fc3f7,stroke:#333,color:#000
        style ATP6V1A_1 fill:#ce93d8,stroke:#333,color:#000
        style lysosomal_acidification fill:#81c784,stroke:#333,color:#000
        style v_ATPase_2 fill:#4fc3f7,stroke:#333,color:#000
        style lysosomal_pH fill:#4fc3f7,stroke:#333,color:#000
        style lysosomal_acidification_3 fill:#81c784,stroke:#333,color:#000
        style protein_degradation fill:#4fc3f7,stroke:#333,color:#000
        style protein_degradation_4 fill:#4fc3f7,stroke:#333,color:#000
        style neurodegeneration fill:#ef5350,stroke:#333,color:#000
        style ATF5 fill:#ce93d8,stroke:#333,color:#000
        style UPRmt fill:#81c784,stroke:#333,color:#000
        style UPRmt_5 fill:#81c784,stroke:#333,color:#000
        style mitochondrial_proteostasi fill:#4fc3f7,stroke:#333,color:#000
        style mitochondrial_proteostasi_6 fill:#4fc3f7,stroke:#333,color:#000
        style seed_induced_protein_misf fill:#4fc3f7,stroke:#333,color:#000
        style HSPA1A fill:#ce93d8,stroke:#333,color:#000
        style protein_folding fill:#4fc3f7,stroke:#333,color:#000
        style HSPA1A_7 fill:#ce93d8,stroke:#333,color:#000
        style chaperone_co_chaperone_co fill:#4fc3f7,stroke:#333,color:#000
        style protein_folding_8 fill:#4fc3f7,stroke:#333,color:#000
        style protein_aggregation fill:#4fc3f7,stroke:#333,color:#000
        style pathological_conformation fill:#4fc3f7,stroke:#333,color:#000
        style benign_or_degradable_form fill:#4fc3f7,stroke:#333,color:#000

    3D Protein Structure

    🧬 KIF5A — Search for structure Click to search RCSB PDB
    🔍 Searching RCSB PDB for KIF5A structures...
    Querying Protein Data Bank API

    Source Analysis

    How do host cell factors influence the conformation and propagation properties of transmitted pathological seeds?

    neurodegeneration | 2026-04-08 | completed

    Community Feedback

    0 0 upvotes · 0 downvotes
    💬 0 comments ⚠ 0 flags ✏ 0 edit suggestions

    No comments yet. Be the first to comment!

    View all feedback (JSON)

    Same Analysis (5)

    Membrane Lipid Composition Therapeutic Modulation
    Score: 0.46 · HMGCR
    Phase Separation Modulation Therapy
    Score: 0.46 · FUS
    Chaperone Network Reprogramming Therapy
    Score: 0.46 · HSPA1A
    Lysosomal pH Gradient Manipulation
    Score: 0.46 · ATP6V1A
    Ribosomal Stress Response Exploitation
    Score: 0.46 · LTN1
    → View all analysis hypotheses
    Public annotations (0)Annotate on Hypothes.is →
    No public annotations yet.